Treatment strategy of gastrointestinal stromal tumors in the background of COVID-19 / 中华胃肠外科杂志
Chinese Journal of Gastrointestinal Surgery
; (12): 825-829, 2021.
Article
in Zh
| WPRIM
| ID: wpr-922734
Responsible library:
WPRO
ABSTRACT
COVID-19, caused by SARS-COV-2, has the characteristics of world epidemic, highly infectious and large base of death. In China, transmission route of SARS-COV-2 has been contained so effectively that COVID-19 has been well controlled due to the proactive national prevention and control strategy. However, not only does it bring a huge impact on the existing medical structure model, but also an objective impact on the treatment of patients with chronic diseases such as malignant tumors. Based on the progress reported in the domestic and international literatures and the actual management experience of our team, this paper reflects on the treatment strategies for patients with gastrointestinal stromal tumor (GIST) during the epidemic period of COVID-19. We focus on risk stratification for primary GIST and forming treatment strategies accordingly. Major considerations include the impact of delayed operation, the burden of medical resources, the waiting time for elective operation, and the principle of emergency operation. In addition, we focus on the level of evidence for non-surgical approaches with a view to developing a holistic strategy of "priority management principles" to guide clinical treatment in the context of limited resources and different GIST priorities.
Key words
Full text:
1
Index:
WPRIM
Main subject:
China
/
Gastrointestinal Stromal Tumors
/
SARS-CoV-2
/
COVID-19
Limits:
Humans
Country/Region as subject:
Asia
Language:
Zh
Journal:
Chinese Journal of Gastrointestinal Surgery
Year:
2021
Type:
Article